Bausch + Lomb announced the U.S. commercial launch of MIEBO for the treatment of the signs and symptoms of dry eye disease. MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO:
- Bausch + Lomb announces expiration of Hart-Scott waiting period to buy XIIDRA 5%
- Bausch + Lomb price target raised to $19 from $18 at Barclays
- Bausch + Lomb files automatic mixed securities shelf
- Bausch + Lomb raises FY23 revenue view to $3.95B-$4.00B from $3.90B-$3.95B
- Bausch + Lomb reports Q2 adjusted EPS 18c, consensus 14c